-
2023-510240-20-00
4
2022-10-05
Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2024-512822-28-00
1
2022-08-08
Advanced or metastatic solid tumors
-
2024-511635-94-00
4
2022-07-11
Relapsed or Refractory Plasmablastic lymphoma
-
2024-517752-35-00
1
2022-04-04
Advanced, metastatic, or recurrent solid mesothelin-expressing maligna
-
2024-518374-13-00
6
2022-02-28
Active progressive multiple sclerosis course after an initial relapse
-
2023-509290-22-00
6
2022-01-21
Severe Symptomatic Aortic Stenosis
-
2024-514687-33-00
4
2021-12-21
Previously Untreated Chronic Lymphophatic Leukaemia
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-507202-14-00
7
2021-04-29
Upper limb spasticity after stroke or traumatic brain injury
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-504888-16-00
9
2020-10-05
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
-
2024-516612-16-00
4
2020-06-17
gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
-
2024-517200-10-00
4
2020-01-31
Advanced non-small-cell lung cancer
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518901-16-00
4
2019-07-29
RIS (Radiologically Isolated Syndrome)
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer